Ascletis Pharma Inc.
1672
Rank in Stocks
#11062
Ascletis Pharma Inc., a biotechnology company, engages in the research and... Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Share Price
$0.56085072
Last synced: 2026-11-19
Market Cap
$583.17M
Change (1 day)
0.70%
Change (1 year)
-69.58%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Ascletis Pharma Inc. (1672)
Category
Healthcare
Operating Margin for Ascletis Pharma Inc. (1672)
Operating Margin as of November 2026 TTM: -70,395.30%
According to Ascletis Pharma Inc.'s latest financial reports, its current operating margin (TTM) is -70,395.30%. At the end of 2025 the company had an operating margin of -23,853.94%.
Operating Margin history for Ascletis Pharma Inc. from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -70,395.30% | 195.11% |
| 2025 | -23,853.94% | 3.60% |
| 2024 | -23,025.64% | 4,240.86% |
| 2023 | -530.44% | -16.59% |
| 2022 | -635.94% | 117.32% |
| 2021 | -292.63% | -52.82% |
| 2020 | -620.30% | 2,852.40% |
| 2019 | -21.01% | -73.91% |
| 2018 | -80.52% | -56.55% |
| 2017 | -185.33% | 42.96% |
| 2016 | -129.64% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -100.00% |
US
|
|
| 33.87% | -100.00% |
US
|
|
| -116.04% | -100.00% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Ascletis Pharma Inc.'s operating margin
What is Ascletis Pharma Inc.'s operating margin?
Ascletis Pharma Inc.'s operating margin is -70,395.30%, as of Nov 2026.
What was Ascletis Pharma Inc.'s operating margin in 2025?
In 2025, Ascletis Pharma Inc.'s operating margin was -23,853.94%, compared with -23,025.64% in 2024.
How has Ascletis Pharma Inc.'s operating margin changed since 2020?
From 2020 to 2025, Ascletis Pharma Inc.'s operating margin was highest in 2021 (-292.63%) and lowest in 2025 (-23,853.94%).
How does Ascletis Pharma Inc.'s operating margin compare with similar companies?
Ascletis Pharma Inc.'s operating margin (-70,395.30%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.